Tag: OSE
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclin… –...
Regulatory News:
OSE Immunotherapeutics SA FR presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics...
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023...
Tedopi® is the Company's Most Advanced Product in Clinical Development
ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi® to chemotherapy in...
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses fr… –...
At American Association for Cancer...